It's not an 80% chance of success. The trial is 80% powered for a 33% increase in median survival, which was based on the TAX327 MS of 18.9 months for the intent to treat group.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.